Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Gilead Sciences, Inc.

Market Cap 154B 794B 134B 124B 116B 217B 14,493B 219B 1,469B 571B 7,131B 577B 564B 24,792B P/E 2026 *
-44.3x
P/E 2027 * 16.1x
Enterprise Value 163B 844B 142B 131B 124B 231B 15,396B 233B 1,561B 606B 7,575B 613B 599B 26,336B EV / Sales 2026 *
5.36x
EV / Sales 2027 * 4.73x
Free-Float
99.87%
Yield 2026 *
2.62%
Yield 2027 * 2.68%
1 day+1.99%
1 week+1.99%
Current month-6.03%
1 month-2.29%
3 months-15.52%
6 months-3.20%
Current year-6.64%
1 week 312.48
Extreme 312.48
321.15
1 month 312.48
Extreme 312.48
342.39
Current year 312.48
Extreme 312.48
396.35
1 year 293.72
Extreme 293.72
396.35
3 years 163.57
Extreme 163.57
396.35
5 years 132.24
Extreme 132.24
396.35
10 years 102.29
Extreme 102.29
396.35
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Change 5-day change 1-year change 3-year change Capi.($)
+1.99%+1.99% - - 156B
-1.21%-3.33%+38.84%+145.38% 992B
-2.48%-4.23%+49.88%+39.07% 564B
-2.14%-3.76%+16.72%+56.15% 391B
-1.18%+0.68%+24.66%+16.53% 330B
-2.36%-2.30%+23.37%+11.59% 280B
-2.45%-0.84%+23.51%+30.06% 279B
-1.91%-1.06%-42.60%-49.25% 196B
-1.19%-0.04%+16.39%+47.00% 184B
-2.74%-1.52%+5.04%-37.07% 148B
Average -0.53%+0.19%+17.31%+28.83% 373.69B
Weighted average by Cap. -0.38%-0.59%+26.71%+59.09%

Financials

2026 *2027 *
Net sales 30.48B 158B 26.6B 24.52B 23.08B 43.07B 2,875B 43.45B 291B 113B 1,414B 114B 112B 4,918B 32.45B 168B 28.32B 26.11B 24.58B 45.86B 3,061B 46.26B 310B 120B 1,506B 122B 119B 5,236B
Net income -3.37B -17.43B -2.94B -2.71B -2.55B -4.77B -318B -4.81B -32.25B -12.52B -157B -12.66B -12.39B -544B 9.6B 49.63B 8.38B 7.73B 7.27B 13.57B 906B 13.69B 91.83B 35.66B 446B 36.04B 35.27B 1,549B
Net Debt 9.57B 49.45B 8.35B 7.7B 7.25B 13.52B 903B 13.64B 91.5B 35.53B 444B 35.91B 35.14B 1,544B -96.43M -498M -84.15M -77.58M -73.04M -136M -9.1B -137M -922M -358M -4.48B -362M -354M -15.56B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-06-16 321.15 R$ +1.99% 166
26-06-15 314.88 R$ +0.32% 8
26-06-12 313.88 R$ -0.32% 2
26-06-10 314.88 R$ -3.05% 6
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
125.45USD
Average target price
157.57USD
Spread / Average Target
+25.60%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!